1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ADA: Zepbound Could Take Sleep Apnea Patients Off CPAP

 
• By Elizabeth Cairns

Lilly’s incretin looks set to add obstructive sleep apnea to its label – an indication in which Novo Nordisk has so far shown no interest.    

Eli Lilly logo sign - San Diego, California, USA - 2020
• Source: Shutterstock/Michael Vi

Eli Lilly and Company’s incretin drug tirzepatide is playing catch-up to Novo Nordisk A/S’s semaglutide in many disorders. In obese patients with obstructive sleep apnea, however, it is ahead of the competition, and new data from the pivotal SURMOUNT-OSA trial suggest that tirzepatide might amount to a cure in some of these patients.

Key Takeaways
  • New SURMOUNT-OSA data show that Lilly’s tirzepatide allowed some obese obstructive sleep apnea patients to have resolution of the condition.

SURMOUNT-OSA had been toplined a hit on its primary endpoint in April, with tirzepatide at either 10mg or 15mg for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

More from R&D

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.